AZN AstraZeneca
AstraZeneca earnings company data as of 9:48 AM ET 9/15
- 1 of 1 EPS beats
History
2 periods · newest first · EPS & Rev stacked
| Period | Date | Metric | Estimate | Actual | Result |
|---|---|---|---|---|---|
| FY2026 Q3 | 5 Nov | EPS | 2.17 | — | — |
| Rev | — | — | — | ||
| FY2026 Q2 | 27 Jul | EPS | 2.50 | 2.63 | Beat +5.2% |
| Rev | — | — | — |
Who owns this among featured managers 13F portfolio weights · not free-float
SEC filings
Recent issuer filings from EDGAR · 25 shown · open Filing / Doc on SEC.gov
| Filed | Form | Detail | Links |
|---|---|---|---|
| 6-K | UPDATE ON SERENA-4 PHASE III TRIAL | Filing Doc | |
| 6-K | IMFINZI+IMDELLTRA IMPROVED OS IN SMALL CELL LUNG | Filing Doc | |
| 6-K | ETCAMAH APPROVED IN THE US FOR HR+ BREAST CANCER | Filing Doc | |
| 6-K | TOTAL VOTING RIGHTS | Filing Doc | |
| 6-K | ADMISSION OF FURTHER SECURITIES TO TRADING | Filing Doc | |
| 6-K | TAGRISSO + ORPATHYS IMPROVED PFS IN 1L EGFRM LUNG | Filing Doc | |
| 6-K | ASTRAZENECA COMPLETES AGREEMENT FOR ZEGFROVY | Filing Doc | |
| 6-K | DIRECTORATE CHANGE | Filing Doc | |
| 6-K | ENHERTU APPROVED IN EU FOR 1L HER2-POSITIVE MBC | Filing Doc | |
| 6-K | ADMISSION TO TRADING - EUR2.55 BILLION BOND OFFERING | Filing Doc | |
| 6-K | TEZSPIRE CROSSING TRIAL MET PRIMARY ENDPOINTS | Filing Doc | |
| 6-K | ASTRAZENECA PRICES A EUR2.55 BILLION BOND OFFERING | Filing Doc | |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | Filing Doc | |
| 6-K | TAGRISSO+ORPATHYS IMPROVED PFS & OS IN EGFRM LUNG | Filing Doc | |
| 6-K | UPDATE ON EVOLVE-LUNG02 PHASE III TRIAL | Filing Doc | |
| 6-K | ENHERTU IMPROVED PFS IN 1L HER2M LUNG CANCER | Filing Doc | |
| 6-K | ADMISSION OF FURTHER SECURITIES TO TRADING | Filing Doc | |
| 6-K | TOTAL VOTING RIGHTS | Filing Doc | |
| 6-K | DATROWAY APPROVED IN EU FOR TNBC | Filing Doc | |
| 6-K | FORM 6-K | Filing Doc | |
| 6-K | SONE-VE IMPROVED SURVIVAL IN GASTRIC CANCERS | Filing Doc | |
| 6-K | UPDATE ON ULTOMIRIS PHASE III TRIAL IN HSCT-TMA | Filing Doc | |
| 6-K | ETCAMAH APPROVED IN THE EU FOR ER+ BREAST CANCER | Filing Doc | |
| 6-K | ASTRAZENECA LICENSES NOVEL EGFR INHIBITOR | Filing Doc | |
| 6-K | UPDATE ON CARDIO-TTRANSFORM PHASE III TRIAL | Filing Doc |
No filings match this filter.
Consensus estimates · SEC filings remain the official record · not investment advice